β-lactamase–negative bacteria
1 drugsPredictive biomarker for patient selection in 7 indications
1
Approved Drugs
7
Indications
1
Companies
β-lactamase–negative bacteria is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 7 indications including Ear, Nose, and Throat Infections, Genitourinary Tract Infections, Skin and Skin Structure Infections. Explore the targeted therapies, indications, testing methods, and companies developing β-lactamase–negative bacteria drugs below.
Search β-lactamase–negative bacteria Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting β-lactamase–negative bacteria
| Drug | Company | Therapeutic Area |
|---|---|---|
| AMOXIL | US ANTIBIOTICS | Infectious Disease |
β-lactamase–negative bacteria Indications
Ear, Nose, and Throat Infections Genitourinary Tract Infections Skin and Skin Structure Infections Lower Respiratory Tract Infections Gonorrhea Helicobacter pylori Infection Duodenal Ulcer Disease